INVESTOR ALERT: Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire LOS ANGELES -- February 27, 2014 Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed on behalf of all purchasers of the securities of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) between January 9, 2014 and January 10, 2014, inclusive (the “Class Period”). For more information, please contact us toll-free at 888-773-9224, or at 212-682-5340, or by email to firstname.lastname@example.org to discuss this matter. Intercept is a development stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing Intercept’s proprietary bile acid chemistry. The Company’s primary drug compound, obeticholic acid (“OCA”), is in various stages of clinical development for the treatment of cirrhosis and other chronic liver diseases. The complaint filed in the United States District Court for the Southern District of New York alleges that the Company’s January 9, 2014, and January 10, 2014, announcements concerning the Phase 2 clinical trial of OCA for treatment of non-alcoholic steatohepatitis failed to disclose material information. On January 10, 2014, the National Institutes of Health’s National Institute of Diabetes and Digestive Kidney Diseases issued a statement that although the efficacy primary endpoint for OCA had already been met, study participants suffered disproportionate levels of lipid abnormalities. Following this news, Intercept stock dropped from its $445.83 per share closing price on January 10, 2014, to a closing price of $255.12 per share on January 14, 2014. If you purchased Intercept securities during the Class Period, you have until April 22, 2014, to move the Court to serve as lead plaintiff. If you wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at 888-773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at 212-682-5340, by e-mail to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact: Glancy Binkow & Goldberg LLP, Los Angeles, CA Michael Goldberg, 888-773-9224 or Glancy Binkow & Goldberg LLP, New York, NY Gregory Linkh, 212-682-5340 or 888-773-9224 firstname.lastname@example.org www.glancylaw.com
INVESTOR ALERT: Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. Announced by Glancy Binkow & Goldberg LLP
Press spacebar to pause and continue. Press esc to stop.